Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
John N. Allan, Javier Pinilla‐Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte Yimer, Renee Ward, Gary D Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Abstract
Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase
Topics & Concepts
Bruton's tyrosine kinaseIbrutinibCancer researchTyrosine kinaseTyrosine-kinase inhibitorChemistryPharmacologyMedicineLeukemiaInternal medicineChronic lymphocytic leukemiaReceptorCancerChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders